AcouSort AB (publ) (ACOU.ST)
SEK 3.72
(-0.8%)
SEK 3.72
(-0.8%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 2.08 Million SEK | 29.27% |
| 2022 | 1.6 Million SEK | 158.27% |
| 2021 | 623 Thousand SEK | -9.05% |
| 2020 | 685 Thousand SEK | -15.43% |
| 2019 | 810 Thousand SEK | -12.34% |
| 2018 | 924 Thousand SEK | -12.42% |
| 2017 | 1.05 Million SEK | 1818.18% |
| 2016 | 55 Thousand SEK | 133.13% |
| 2015 | -166 Thousand SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 2.1 Million SEK | 1.15% |
| 2024 Q2 | 2.21 Million SEK | 5.37% |
| 2023 Q2 | 2.15 Million SEK | 10.06% |
| 2023 FY | 2.08 Million SEK | 29.27% |
| 2023 Q4 | 2.08 Million SEK | -7.64% |
| 2023 Q1 | 1.95 Million SEK | 21.69% |
| 2023 Q3 | 2.25 Million SEK | 4.5% |
| 2022 Q2 | 892 Thousand SEK | 23.37% |
| 2022 FY | 1.6 Million SEK | 158.27% |
| 2022 Q4 | 1.6 Million SEK | 167.28% |
| 2022 Q1 | 723 Thousand SEK | 16.05% |
| 2022 Q3 | 602 Thousand SEK | -32.51% |
| 2021 Q4 | 623 Thousand SEK | -10.62% |
| 2021 Q2 | 663 Thousand SEK | -11.95% |
| 2021 Q1 | 753 Thousand SEK | 9.93% |
| 2021 Q3 | 697 Thousand SEK | 5.13% |
| 2021 FY | 623 Thousand SEK | -9.05% |
| 2020 Q1 | 753 Thousand SEK | -7.04% |
| 2020 Q3 | 691 Thousand SEK | 2.07% |
| 2020 FY | 685 Thousand SEK | -15.43% |
| 2020 Q4 | 685 Thousand SEK | -0.87% |
| 2020 Q2 | 677 Thousand SEK | -10.09% |
| 2019 Q1 | 938 Thousand SEK | 1.52% |
| 2019 Q3 | 938 Thousand SEK | 0.0% |
| 2019 Q4 | 810 Thousand SEK | -13.65% |
| 2019 FY | 810 Thousand SEK | -12.34% |
| 2019 Q2 | 938 Thousand SEK | 0.0% |
| 2018 Q3 | 1.28 Million SEK | 11.88% |
| 2018 FY | 924 Thousand SEK | -12.42% |
| 2018 Q4 | 924 Thousand SEK | -27.87% |
| 2018 Q2 | 1.14 Million SEK | 8.53% |
| 2018 Q1 | 1.05 Million SEK | 0.0% |
| 2017 Q3 | 603 Thousand SEK | 215.71% |
| 2017 Q4 | 1.05 Million SEK | 74.96% |
| 2017 FY | 1.05 Million SEK | 1818.18% |
| 2017 Q2 | 191 Thousand SEK | 15.06% |
| 2017 Q1 | 166 Thousand SEK | 201.82% |
| 2016 FY | 55 Thousand SEK | 133.13% |
| 2016 Q4 | 55 Thousand SEK | 106.73% |
| 2016 Q3 | -817 Thousand SEK | 0.0% |
| 2015 Q4 | -77 Thousand SEK | 0.0% |
| 2015 FY | -166 Thousand SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alzinova AB (publ) | -3.27 Million SEK | 163.453% |
| Amniotics AB (publ) | 534 Thousand SEK | -289.513% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 89.818% |
| Genovis AB (publ.) | 14.9 Million SEK | 86.045% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 94.096% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 341.02% |
| Saniona AB (publ) | 1.00 SEK | -207999900.0% |
| Simris Alg AB (publ) | 1.09 Million SEK | -90.651% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | 83300.0% |
| Camurus AB (publ) | 100.95 Million SEK | 97.94% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 48.438% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 140073.082% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | -1950.00 SEK | 106766.667% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 227.921% |
| NextCell Pharma AB | 545.23 Thousand SEK | -281.485% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 98.053% |
| Xintela AB (publ) | 398 Thousand SEK | -422.613% |
| Ziccum AB (publ) | -4.18 Million SEK | 149.654% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 565.339% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 95.249% |
| CombiGene AB (publ) | -1.79 Million SEK | 215.62% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 91.351% |
| Intervacc AB (publ) | 10.48 Million SEK | 80.158% |
| Alligator Bioscience AB (publ) | 2.00 SEK | -103999900.0% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 129.148% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Corline Biomedical AB | -3.85 Million SEK | 153.928% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -207900.0% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 77.062% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | 33.968% |
| Biovica International AB (publ) | 2.19 Million SEK | 5.412% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -207999900.0% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | -197.143% |
| 2cureX AB (publ) | -1000.00 SEK | 208100.0% |
| I-Tech AB | 4.28 Million SEK | 51.402% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 78.758% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 142.199% |
| Nanologica AB (publ) | 2.97 Million SEK | 30.037% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 82.438% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 747.683% |
| Oncopeptides AB (publ) | 2.42 Million SEK | 14.227% |
| Pila Pharma AB (publ) | 1.00 SEK | -207999900.0% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | -102.335% |